Mycosis fungoides

It is a lymphoma — a cancer that starts in lymphocytes, the white blood cells of the immune system — that shows itself in the skin.

It is not a skin cancer, and this matters more than it sounds. Skin cancer develops from skin cells. Skin lymphoma develops when lymphocytes grow out of control in the skin. Sun exposure is not the cause, and it is not something that can be cut out.

The name is old and misleading. There is no fungus involved. It was named in the nineteenth century for the appearance of the raised lesions in advanced disease, which most people never develop.

It is the most common cutaneous T-cell lymphoma, making up roughly half to three fifths of them. Cancer Research UK describes it as a very slow-growing type.

It moves through recognisable phases in the skin, and the names are worth knowing because they map onto how it is staged: flat, thin, discoloured patches; then raised, thickened plaques; then, in a minority, tumours — raised nodules a centimetre or more across.

Early patches turn up most often on the torso and buttocks and are routinely mistaken for eczema, dermatitis or psoriasis.

The cause is not known. None of the sources we read states an established cause, and we are not going to offer a trigger or a risk factor dressed up as one.

Nothing in these sources describes it as inherited or as contagious.

Because this is a lymphoma rather than a skin cancer, sun exposure is not a cause. Readers reasonably assume otherwise, which is why it is worth saying outright.

It is usually diagnosed in middle age or later — the mean age in one large UK cohort was 54, and reviews give a typical range of 50 to 60.

Recorded incidence differs by sex and by ethnicity in US registry data. Those are differences in what registries record, shaped partly by access to dermatology and by how the diagnosis gets made. They are not causes and not anything a person controls.

For most people it behaves as a long-term skin condition rather than a crisis. Lymphoma Action puts it plainly: in most cases it does not affect life expectancy and is treated more like a chronic condition.

Staging here is not the plain I to IV used for most cancers. It records four things: how much skin is involved and what kind of lesion, whether lymph nodes are involved, whether organs are, and whether the blood is. Early stage means IA to IIA. Advanced means IIB and above.

Most people are diagnosed early. In a cohort of 1,502 people at a UK specialist unit, 71% presented with early-stage disease; published series elsewhere run higher still.

Most early-stage disease does not progress. In that same cohort, the risk of progressing within ten years from the earliest stage was 12%. EBMT’s recommendations state that around a third of early-stage patients progress to advanced stages — the two figures come from different sources and different populations, and we are giving you both rather than picking one.

Advanced disease is a different disease in outcome terms, and it would be wrong to blur them. The NCI reports that more than half of people with stage III to IV disease die of it, with a median survival of about five years.

The lymphoma changing into a more aggressive large-cell form is uncommon — the NCI describes it as a rare event occurring in under 5% — and it carries a poorer outlook.

Blood involvement is not part of early mycosis fungoides. That is what defines the related condition, Sézary syndrome, which usually arises in its own right rather than as what this becomes: only 3% of 1,422 people in one study progressed from one to the other over a median of 14.5 years.

Many people do not need treatment straight away. Monitoring is a legitimate first answer rather than a delay, and reviews describe it as appropriate for low-risk earliest-stage disease.

When treatment is needed for early-stage disease, it is skin-directed — aimed at the skin itself rather than given through the whole body. That is worth spelling out, because people assume all cancer treatment is systemic.

Strong topical steroid creams can clear patches over four to six weeks.

Chemotherapy applied to the skin as a gel or ointment is another option. Lymphoma Action is honest about it: it can take up to a year to clear patches, the effect may last several months, and the lymphoma usually comes back.

Light treatment is widely used. Narrowband ultraviolet B means two or three sessions a week, usually 15 to 30 of them. A different form combines a drug that makes the skin light-sensitive with ultraviolet A light, and the NCI reports high complete remission rates with it — remission, not cure, and some people stay in it for up to five years.

Radiotherapy can treat single stubborn areas, or the whole skin surface using electrons that penetrate only skin-deep.

For advanced or whole-body redness, blood can be treated outside the body: it is drawn, the white cells separated out, treated with a light-sensitising drug and ultraviolet light, and returned.

Advanced disease may also be treated with drugs given through the whole body — interferon, retinoid drugs, several targeted antibodies, and conventional chemotherapy.

The honest register for all of this is that treatment is a rotation rather than a single course. Skin clears, treatment stops, disease returns, treatment is repeated or changed.

It takes a long time to get the diagnosis. The median from first symptoms is around three years, and many people are treated for eczema, dermatitis or psoriasis first.

If that is your story, here is the thing worth knowing: Lymphoma Action states directly that the time taken to make the diagnosis does not usually affect the prognosis. Those years were frustrating, and on the evidence available they did not cost you the outcome.

The burden of early-stage treatment is time and repetition rather than intensity — light treatment two or three times a week for weeks, ointment applied for up to a year, courses repeated when the skin relapses.

It is visible, and it is on skin a person may or may not be able to cover. None of the sources we read measures what that does to people, so we are not going to attach a number to it — but it is real and it is the part people most often say is under-acknowledged.

Itch is a feature of the more extensive forms and can be relentless.

Who leads the care changes with stage. Dermatology leads early-stage disease. Haematology and a transplant team come into it only if disease is advanced, transformed or not responding.

For the great majority of people reading this page, a donor plays no part at all. EBMT’s 2025 recommendations state that for early-stage disease a donor transplant is generally not indicated, and most people with this diagnosis have early-stage disease.

We want to be direct about that, because this library got it wrong once. This condition was originally classed here as one where a stranger is commonly the match. It is not, and correcting it mattered: a donor appeal on this page would land almost entirely on people with excellent long-term survival and no transplant indication whatsoever.

There is a genuine exception, and it is a small one. EBMT states that people with large cell transformation, with stage IV disease, or with relapsed or refractory stage IIB to III disease should be considered for a donor transplant. Both Cancer Research UK and Lymphoma Action describe this as something a few people with advanced disease have, and only those fit enough for it.

One thing about this disease runs opposite to almost every other lymphoma in this library. Where a transplant does happen here, it uses a donor’s cells rather than the person’s own. A transplant using the patient’s own cells has no established role in this condition — reported responses are frequently short-lived. The reason is that the treatment works through the donor’s immune system recognising and attacking the lymphoma, which the person’s own cells cannot do.

If you are reading this because you are considering joining a registry: people with many different conditions need unrelated donors, and the case for joining rests on those. It does not rest on this page.